Synaptogenix, Inc. (NASDAQ:SNPX – Get Free Report) saw a large decrease in short interest in August. As of August 31st, there was short interest totalling 4,900 shares, a decrease of 53.3% from the August 15th total of 10,500 shares. Based on an average daily volume of 37,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are sold short.
Synaptogenix Stock Performance
NASDAQ:SNPX traded up $0.31 during trading hours on Friday, hitting $3.16. The company’s stock had a trading volume of 28,785 shares, compared to its average volume of 38,357. The stock has a fifty day simple moving average of $3.84 and a 200-day simple moving average of $4.32. Synaptogenix has a twelve month low of $2.72 and a twelve month high of $11.47.
Synaptogenix (NASDAQ:SNPX – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($1.18) earnings per share for the quarter.
Wall Street Analyst Weigh In
Read Our Latest Analysis on Synaptogenix
About Synaptogenix
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
See Also
- Five stocks we like better than Synaptogenix
- Best Stocks Under $5.00
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Dividend Payout Ratio Calculator
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What Are Some of the Best Large-Cap Stocks to Buy?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.